Pluto Immunotherapeutics
Los Angeles, US · Founded 2020 · Delaware corporation
Founders & leadership
CS
Christopher SeetNamed on SEC filing
GM
Gay Miriam CrooksNamed on SEC filing
MC
Mark CohenNamed on SEC filing
AM
Amelie Montel-HagenNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$5M disclosed across 2 rounds · 2020–2021
▶$2.8MraisedJan 2022 · 20 investors · BiotechnologyRule 506(b)
▶$2.8MraisedJan 2022 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark CohenDirector
- Amelie Montel-HagenExecutive Officer, Director
- Christopher SeetDirector
- Gay CrooksDirector
- Offering amount
- $3M
- Amount sold
- $2.8M
- Minimum investment
- $10K
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$2.2MraisedDec 2020 · 30 investors · Other Health CareRule 506(b)
▶$2.2MraisedDec 2020 · 30 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Christopher SeetDirector
- Gay Miriam CrooksDirector
- Mark CohenDirector
- Amelie Montel-HagenDirector
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- Minimum investment
- $25K
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Pluto Immunotherapeutics raised?
- Pluto Immunotherapeutics has disclosed $5M raised across 2 rounds.
- Where is Pluto Immunotherapeutics headquartered?
- Pluto Immunotherapeutics is headquartered in Los Angeles, US.